Stay updated on Surufatinib and Tislelizumab Combination in Solid Tumors Clinical Trial
Sign up to get notified when there's something new on the Surufatinib and Tislelizumab Combination in Solid Tumors Clinical Trial page.

Latest updates to the Surufatinib and Tislelizumab Combination in Solid Tumors Clinical Trial page
- Check6 days agoNo Change Detected
- Check13 days agoChange DetectedAdded a funding/operating status notice and a new version tag (v3.2.0); removed two specific cancer diagnoses and an older version tag (v3.1.0).SummaryDifference2%
- Check20 days agoChange DetectedVersion update: from v3.0.2 to v3.1.0. The change is limited to the revision label; no other page content or data appears to be altered.SummaryDifference0.0%
- Check28 days agoNo Change Detected
- Check35 days agoChange DetectedVersion updated from v3.0.1 to v3.0.2; the 'Back to Top' element was removed, with no substantive content changes.SummaryDifference0.1%
- Check42 days agoChange DetectedThe web page has been updated from version 3.0.0 to version 3.0.1, indicating a revision in the content. There are no significant changes to core content or other important elements.SummaryDifference0.1%
- Check49 days agoChange DetectedThe web page has been updated to include new facility and location information, as well as additional resources related to various gastrointestinal diseases and neoplasms. Notably, the names of specific drugs and conditions have been revised, reflecting a shift in focus towards more current medical topics.SummaryDifference4%
- Check56 days agoChange DetectedThere are no significant changes to the web page content.SummaryDifference0.6%
Stay in the know with updates to Surufatinib and Tislelizumab Combination in Solid Tumors Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Surufatinib and Tislelizumab Combination in Solid Tumors Clinical Trial page.